Beam Therapeutics to Participate at the Wells Fargo 2022 Healthcare Conference
Beam Therapeutics (Nasdaq: BEAM), a leading biotechnology firm focused on precision genetic medicines, announced that CEO John Evans will present at the Wells Fargo 2022 Healthcare Conference on September 8, 2022, at 9:45 a.m. ET in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Beam Therapeutics (Nasdaq: BEAM), a leading biotechnology firm focused on precision genetic medicines, announced that CEO John Evans will present at the Wells Fargo 2022 Healthcare Conference on September 8, 2022, at 9:45 a.m. ET in Boston. The event will be accessible via a live webcast on the company's investor website and archived for 60 days. Beam specializes in base editing technology, enabling precise modifications in genetic sequences to develop effective therapeutic strategies for serious diseases. The company is committed to achieving life-long cures through cutting-edge scientific advancements.
Details
News Market Reaction – BEAM
The recorded move for BEAM in the trading session of this news was +1.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will present at the Wells Fargo 2022 Healthcare Conference on Thursday, September 8, 2022 at 9:45 a.m. ET in Boston.
A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contacts:
Investors:
Chelcie Lister
THRUST Strategic Communications
chelcie@thrustsc.com
Media:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.